de Carvalho Jozélio Freire, Skare Thelma L
Núcleo de Pesquisa em Doenças Crônicas não Transmissíveis (NUPEN), School of Nutrition from the Federal University of Bahia, Salvador, Bahia, Brazil.
Serviço de Reumatologia, Hospital Universitário Evangélico Mackenzie, Curitiba, PR, Brazil.
Autoimmun Rev. 2025 Jan 3;24(1):103695. doi: 10.1016/j.autrev.2024.103695. Epub 2024 Nov 20.
Dyslipidemia is described in several autoimmune conditions. Lipoprotein lipase (LPL) is responsible for triglyceride breakdown. Anti-LPL antibodies have been described.
To review articles on anti-LPL antibodies in autoimmune and non-autoimmune diseases.
Twenty-two articles were found: 9 case reports and 13 observational studies. In 5 of 9 case reports, hypertriglyceridemia normalized after immunosuppressive treatment. The observational studies showed the prevalence and associations of anti-LPL antibodies: systemic lupus erythematosus, found in 37.8 % to 71 % of patients and associated with nephritis, disease activity, and the presence of anti-dsDNA antibodies. In myositis, the prevalence ranged from 4 % to 43 % without any reported association. In scleroderma, they were found in 35 % to 42 % and associated with skin and lung fibrosis, heart involvement, and the presence of anti-topoisomerase-1 antibodies. In Sjögren's syndrome and rheumatoid arthritis, they were found in a minority of individuals. They were absent in Behçet's disease, antiphospholipid antibody syndrome, juvenile idiopathic arthritis, juvenile dermatomyositis, and Takayasu arteritis. Three studies were conducted on dyslipidemic patients without autoimmune conditions, and in one of them, anti-LPL antibodies were associated with necrosis in atherosclerotic plaques.
Anti-LPL antibodies were detected in several autoimmune and non-autoimmune diseases, mainly connective tissue diseases, and were associated with increased triglyceride levels. These antibodies may contribute to the accelerated atherogenesis seen in these patients.
血脂异常在多种自身免疫性疾病中均有描述。脂蛋白脂肪酶（LPL）负责甘油三酯的分解代谢。抗LPL抗体也已被报道。
综述关于自身免疫性和非自身免疫性疾病中抗LPL抗体的文章。
共检索到22篇文章，其中9篇病例报告，13篇观察性研究。9篇病例报告中有5篇显示，免疫抑制治疗后高甘油三酯血症恢复正常。观察性研究显示了抗LPL抗体的患病率及相关性：系统性红斑狼疮患者中，抗LPL抗体的患病率为37.8%至71%，且与肾炎、疾病活动度及抗双链DNA抗体的存在相关。在肌炎患者中，抗LPL抗体的患病率为4%至43%，未发现与其他因素有相关性。在硬皮病患者中，抗LPL抗体的患病率为35%至42%，且与皮肤和肺纤维化、心脏受累及抗拓扑异构酶-1抗体的存在相关。在干燥综合征和类风湿关节炎患者中，仅少数个体检测到抗LPL抗体。白塞病、抗磷脂抗体综合征、幼年特发性关节炎、幼年皮肌炎和大动脉炎患者中未检测到抗LPL抗体。对无自身免疫性疾病的血脂异常患者进行了3项研究，其中1项研究显示抗LPL抗体与动脉粥样硬化斑块坏死相关。
在多种自身免疫性和非自身免疫性疾病中均检测到抗LPL抗体，主要为结缔组织病，且与甘油三酯水平升高相关。这些抗体可能促使这些患者动脉粥样硬化进程加速。
